Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- New Proposed Values For PCI Codes | 2026 Medicare PFS Proposed RuleThe Centers for Medicare and Medicaid Services (CMS) has proposed updated values to the PCI family of codes in the proposed 2026 Medicare Physician Fee Schedule (PFS), following revisions made by the CPT Editorial Panel in February 2024 and revaluation by the American Medical Association Relative Value Scale Update Committee (RUC) in April 2024.
- Early Administration of Heparin at First Medical Contact for PPCI of STEMI PatientsThe goal of the HELP-PCI trial was to determine the efficacy and safety of administering unfractionated heparin at first medical contact versus during cardiac catheterization only in patients with ST-segment elevation myocardial infarction (STEMI).
- HELIOS-B Analyses: Vutrisiran Significantly Affects Biomarkers, Echocardiographic ParametersTwo post-hoc analyses of the HELIOS-B trial published Aug. 4 in JACC found that vutrisiran had significant effect on both biomarkers like NT-proBNP and troponin I levels and echocardiographic measures of biventricular systolic and diastolic function in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). Furthermore, both these biomarkers and echocardiographic measures provide critical prognostic information.
- FDA Update: Boston Scientific Warns of WATCHMAN Access System IssueThe U.S. Food and Drug Administration (FDA) has announced that certain WATCHMAN Access Systems have updated use instructions to address risk of air embolism.
- ACCEL Lite: LAAO vs. DOAC for Stroke Prevention in AFibIn this interview, Drs. Anthony N. DeMaria and Dhanunjaya Lakkireddy explore the evolving landscape of stroke prevention in patients with atrial fibrillation, focusing on the comparison between traditional blood thinners and LAAO.